TABLE 2.
Immune checkpoint inhibitors
| Immune checkpoint inhibitor | Target molecule | Target cancer |
|---|---|---|
| Ipilimumab | CTLA‐4 | Malignant melanoma, Renal cell carcinoma, (combination with nivolumab) MSI‐H CRC |
| Tremelimumab | CTLA‐4 | (combination with Durvalumab) Non‐small cell lung cancer, Head and neck cancer |
| Pembrolizumab | PD‐1 | Malignant melanoma, Non‐small cell lung cancer, MSI‐H solid tumors |
| Nivolumab | PD‐1 | Malignant melanoma, Non‐small cell lung cancer, Head and neck cancer, Gastric cancer |
| Spartalizumab | PD‐1 | BRAF mutated maligant melanoma |
| Cemiplimab | PD‐1 | Squamous cell skin cancer |
| Atezolizumab | PD‐L1 | Breast cancer, Non‐small cell lung cancer, Small cell lung cancer |
| Avelumab | PD‐L1 | Merkel cell cancer, Renal cell carcinoma |
| Durvalumab | PD‐L1 | Non‐small cell lung cancer |